Chakma Justin
Insider CIK 1951238 · SPRY Chief Business Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2026-01-02 | 2026-01-05 | 240,000 | — | $0 | 240,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2025-11-12 | 2025-11-14 | 30,000 | — | $0 | 89,047 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2025-11-12 | 2025-11-14 | 30,000 | $0.84 | $25.2K | 166,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2025-11-12 | 2025-11-14 | 30,000 | $8.91 | $267.3K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2025-11-12 | 2025-11-14 | 136,380 | $8.86 | $1.21M | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2025-01-02 | 2025-01-03 | 274,100 | — | $0 | 274,100 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-13 | 2024-12-13 | 27,272 | — | $0 | 55,461 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-13 | 2024-12-13 | 27,272 | $1.44 | $39.3K | 163,652 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-13 | 2024-12-13 | 27,272 | $12.06 | $328.9K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-12 | 2024-12-13 | 117,333 | — | $0 | 119,047 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-12 | 2024-12-13 | 117,333 | $12.27 | $1.44M | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-12 | 2024-12-13 | 117,333 | $0.84 | $98.6K | 253,713 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-10 | 2024-12-12 | 50,000 | — | $0 | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-10 | 2024-12-12 | 50,000 | $13.15 | $657.5K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-10 | 2024-12-12 | 50,000 | $0.84 | $42.0K | 186,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-06 | 2024-12-06 | 50,000 | — | $0 | 50,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-06 | 2024-12-06 | 50,000 | $14.23 | $711.5K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-06 | 2024-12-06 | 50,000 | $0.84 | $42.0K | 186,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-05 | 2024-12-06 | 49,640 | — | $0 | 100,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-05 | 2024-12-06 | 49,640 | $0.84 | $41.7K | 186,020 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-05 | 2024-12-06 | 49,640 | $14.13 | $701.4K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-04 | 2024-12-06 | 45,000 | — | $0 | 149,640 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-04 | 2024-12-06 | 45,000 | $0.84 | $37.8K | 181,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-04 | 2024-12-06 | 45,000 | $13.95 | $627.8K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-03 | 2024-12-04 | 41,740 | — | $0 | 194,640 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-03 | 2024-12-04 | 3,260 | — | $0 | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-03 | 2024-12-04 | 41,740 | $0.84 | $35.1K | 181,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-03 | 2024-12-04 | 3,260 | $0.84 | $2.7K | 139,640 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-03 | 2024-12-04 | 45,000 | $13.19 | $593.5K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise deriv | 2024-12-02 | 2024-12-04 | 45,000 | — | $0 | 3,260 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-12-02 | 2024-12-04 | 45,000 | $13.67 | $615.1K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | M Exercise | 2024-12-02 | 2024-12-04 | 45,000 | $0.84 | $37.8K | 181,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-27 | 2024-11-27 | 25,000 | $14.39 | $359.8K | 136,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-26 | 2024-11-27 | 42,186 | $14.05 | $592.7K | 161,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-25 | 2024-11-27 | 32,814 | $14.00 | $459.4K | 203,566 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2024-01-02 | 2024-01-04 | 350,000 | — | $0 | 350,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2023-01-03 | 2023-01-05 | 165,000 | — | $0 | 165,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2022-11-08 | 2022-11-10 | 236,380 | — | $0 | 236,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2022-11-08 | 2022-11-10 | 236,380 | — | $0 | 236,380 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2022-11-08 | 2022-11-10 | 48,260 | — | $0 | 48,260 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2022-11-08 | 2022-11-10 | 82,733 | — | $0 | 82,733 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award | 2022-11-08 | 2022-11-10 | 236,380 | — | $0 | 236,380 | SEC↗ |